436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment
Saved in:
| Title: | 436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment |
|---|---|
| Authors: | Ciardiello, F.1 (AUTHOR), Yoshino, T.2 (AUTHOR), Modest, D.P.3 (AUTHOR), Martin Fernandez, L.4 (AUTHOR), Roby, L.4 (AUTHOR), Fougeray, R.4 (AUTHOR), Lockhart, B.P.5 (AUTHOR), Tabernero, J.6 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS733-S734. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
